Development of proximal complement therapeutics occurred because of the need to control C3-mediated extravascular hemolysis (EVH), exposed by C5 inhibition, which increasingly poses a significant risk for patients with PNH [6]. The gene discussed is C5; the disease is paroxysmal nocturnal hemoglobinuria.